0000000000550436

AUTHOR

Giorgio Sesti

showing 21 related works from this author

Insulin-Like Growth Factor-I, Inflammatory Proteins, and Fibrosis in Subjects With Nonalcoholic Fatty Liver Disease

2013

Inflammation may have a pathogenic role in the progression of nonalcoholic fatty liver disease (NAFLD); by contrast, the role of anti-inflammatory molecules has not been addressed. Low circulating levels of the anti-inflammatory molecule IGF-I have been described in subjects with NAFLD.The aim of the study was to elucidate the clinical significance of IGF-I in NAFLD and its relationship with inflammatory biomarkers and fibrosis.We conducted a cross-sectional study and in vitro experiments on hepatic HepG2 cells at the Internal Medicine and Gastrointestinal and Liver Units of the Universities of Catanzaro and Palermo.A total of 221 individuals with NAFLD diagnosed on ultrasonography (cohort …

Malemedicine.medical_specialtyFibrosiEndocrinology Diabetes and MetabolismClinical BiochemistryContext (language use)digestive systemBiochemistryGastroenterologyCell LineEndocrinologyFibrosisInternal medicineNonalcoholic fatty liver diseaseBiopsymedicineHumansClinical significanceInsulin-Like Growth Factor IUltrasonographyAgedInflammationCross-Sectional Studiemedicine.diagnostic_testbusiness.industryBiochemistry (medical)Fatty livernutritional and metabolic diseasesMiddle Agedmedicine.diseaseFibrosisdigestive system diseasesFatty LiverCross-Sectional StudiesLiverLiver biopsyBiological MarkerCohortFemalebusinessBiomarkersHumanThe Journal of Clinical Endocrinology & Metabolism
researchProduct

Serum alkaline phosphatase negatively affects endothelium-dependent vasodilation in naïve hypertensive patients.

2015

Tissue nonspecific alkaline phosphatase, promoting arterial calcification in experimental models, is a powerful predictor of total and cardiovascular mortality in general population and in patients with renal or cardiovascular diseases. For this study, to evaluate a possible correlation between serum alkaline phosphatase levels and endothelial function, assessed by strain gauge plethysmography, we enrolled 500 naïve hypertensives divided into increasing tertiles of alkaline phosphatase. The maximal response to acetylcholine was inversely related to alkaline phosphatase ( r =−0.55; P <0.001), and this association was independent ( r =−0.61; P <0.001) of demographic and classical risk …

Malemedicine.medical_specialtyEndotheliumPopulationRenal functionchemistry.chemical_elementVasodilationCalciumFollow-Up StudieatherosclerosiRisk FactorsInternal medicineInternal MedicinemedicineHumansEndothelial dysfunctioneducationriskeducation.field_of_studybusiness.industryRisk FactorMedicine (all)IncidenceMiddle Agedmedicine.diseaseAlkaline PhosphataseacetylcholinePlethysmographyVasodilationmedicine.anatomical_structureEndocrinologychemistryItalyHypertensionAlbuminuriaAlkaline phosphataseFemaleacetylcholine; alkaline phosphatase; atherosclerosis; hypertension; riskEndothelium Vascularatherosclerosismedicine.symptombusinessHumanFollow-Up StudiesHypertension (Dallas, Tex. : 1979)
researchProduct

COPD significantly increases cerebral and cardiovascular events in hypertensives

2021

AbstractEssential hypertension and chronic obstructive pulmonary disease often coexist in the same patient. The aim of this study was to evaluate whether the addition of chronic obstructive pulmonary disease modifies the risk of cardiovascular events in hypertensives. We enrolled 1728 hypertensives. Study outcomes included fatal and non-fatal cardiovascular stroke and myocardial infarction, and cardiovascular death. During a mean follow-up of 57 months there were 205 major adverse cardiovascular events (2.47 per 100 pts/yr): cardiac (n117; 1.41 per 100 pts/yr) and cerebrovascular (n = 77; 0.93 per 100 pts/yr). In hypertensives with chronic obstructive pulmonary disease we observed a greater…

Malemedicine.medical_specialtyScienceCardiologyPulmonary disease030204 cardiovascular system & hematologyEssential hypertensionArticleCardiovascular deathPulmonary Disease Chronic Obstructive03 medical and health sciencesMedical research0302 clinical medicineInternal medicinemedicineHumansMyocardial infarctionStrokeAgedessential hypertension; chronic obstructive; pulmonary diseaseCOPDMultidisciplinarybusiness.industryIncidenceIncidence (epidemiology)QRespiratory diseaseRMiddle Agedmedicine.diseaseRisk factors030228 respiratory systemHypertensionCardiologyMedicineFemaleCOPD Hypertensionbusiness
researchProduct

Insulin-resistance HCV infection-related affects vascular stiffness in normotensives

2015

BACKGROUND AND AIMS. Arterial stiffness evaluated as pulse wave velocity, is an early marker of vascular damage and an independent predictor for cardiovascular events. We investigated if the insulin resistance/hyperinsulinemia chronic hepatitis C virus infection-related could influence arterial stiffness. METHODS. We enrolled 260 outpatients matched for age, body mass index, gender, ethnicity: 52 with never-treated uncomplicated chronic hepatitis C virus infection (HCV(+)), 104 never-treated hypertensives (HT) and 104 healthy subjects (NT). Pulse wave velocity was evaluated by a validated system employing high-fidelity applanation tonometry. We also measured: fasting plasma glucose and insu…

AdultMalemedicine.medical_specialtySettore MED/09 - Medicina Internamedicine.medical_treatmentArterial stiffness; Chronic hepatitis C virus infection; Insulin resistanceInsulin resistance; chronic hepatitis C virus infection; arterial stiffnessBlood PressurePulse Wave AnalysisBody Mass Indexchemistry.chemical_compoundVascular StiffnessInsulin resistanceRisk FactorsHyperinsulinismInternal medicinemedicineHyperinsulinemiaHumansInsulinPulse wave velocityCreatinineTriglyceridebusiness.industryInsulinInsulin resistanceHepatitis CHepatitis C ChronicMiddle Agedmedicine.diseaseArterial stiffnearterial stiffnessEndocrinologychemistryCase-Control StudiesHypertensionLinear ModelsArterial stiffnessFemaleCardiology and Cardiovascular MedicinebusinessChronic hepatitis C virus infection
researchProduct

Sarcopenia and appendicular muscle mass as predictors of impaired fasting glucose/type 2 diabetes in elderly women

2021

Elderly women exhibit a high risk of type 2 diabetes (T2D), but no definitive data exist about the possible role of postmenopausal increases in visceral adiposity, the loss of lean body mass, or decreases in the sum of the lean mass of arms and legs (appendicular skeletal muscle mass (ASMM)). This retrospective, longitudinal study investigated whether body composition (bioelectrical impedance analysis) predicted the development of impaired fasting glucose (IFG) or T2D in a cohort of 159 elderly women (age: 71 ± 5 years, follow-up: 94 months) from southern Italy (Clinical Nutrition and Geriatric Units of the “Mater Domini” University Hospital in Catanzaro, Calabria region, and the “P. Giacco…

endocrine system diseasesappendicular skeletal muscle mass.Type 2 diabetes030204 cardiovascular system & hematologyBody Mass IndexCohort StudiesEating0302 clinical medicineTX341-641Longitudinal StudiesSettore MED/49 - Scienze Tecniche Dietetiche ApplicateSicilyNutrition and DieteticsHand StrengthdiabetesFastingaging; appendicular skeletal muscle mass; body composition; diabetes; nutrition; sarcopenianutritionItalydiabetes; aging; nutrition; body composition; sarcopenia; appendicular skeletal muscle mass.FemaleBioelectrical impedance analysisappendicular skeletal muscle massmedicine.medical_specialtyWaist030209 endocrinology & metabolismClinical nutritionArticlesarcopenia03 medical and health sciencesMuscular DiseasesDiabetes mellitusInternal medicinemedicineHumansMuscle StrengthMuscle SkeletalAgedRetrospective Studiesbody compositionNutrition. Foods and food supplybusiness.industryagingnutritional and metabolic diseasesImpaired fasting glucosemedicine.diseaseGlucoseDiabetes Mellitus Type 2diabeteSarcopeniaLean body massbusinessFood Science
researchProduct

Liraglutide Increases Serum Levels of MicroRNA-27b, -130a and -210 in Patients with Type 2 Diabetes Mellitus: A Novel Epigenetic Effect

2020

Liraglutide has shown favourable effects on several cardiometabolic risk factors, beyond glucose control. MicroRNAs (miRNAs) regulate gene expression, resulting in post-transcriptional modifications of cell response and function. Specific miRNAs, including miRNA-27b, miRNA-130a, and miRNA-210, play a role in cardiometabolic disease. We aimed to determine the effect of liraglutide on the serum levels of miRNA-27b, miRNA-130a and miRNA-210. Twenty-five subjects with type-2 diabetes mellitus (T2DM), na&iuml

0301 basic medicinemedicine.medical_specialtyEndocrinology Diabetes and Metabolismlcsh:QR1-502IncretinType 2 diabetestype-2 diabetes030204 cardiovascular system & hematologyBiochemistryArticlelcsh:Microbiologyliraglutide; microRNAs; type-2 diabetes; cardiometabolic risk; epigenetic03 medical and health sciences0302 clinical medicineInterquartile rangeDiabetes mellitusInternal medicinecardiometabolic riskMedicineMolecular Biologyliraglutidebusiness.industryLiraglutideType 2 Diabetes MellitusMicroRNAmedicine.diseaseMetforminmicroRNAs030104 developmental biologyEndocrinologybusinessHomeostasisepigeneticmedicine.drugMetabolites
researchProduct

Competitive interaction between chronic obstructive pulmonary disease and CHA2DS2-VASc score in predicting incident atrial fibrillation

2018

Background: Chronic obstructive pulmonary disease (COPD) is a leading cause of morbidity and mortality, and an emerging risk factor for atrial fibrillation (AF). CHADS2 and CHA2DS2-VASc scores are significantly associated with incident AF independently of other risk factors. The aim of this study was to demonstrate a possible interaction between COPD and CHA2DS2-VASc in predicting incident AF. Methods: This observational prospective cohort study included 4322 Caucasians with cardiovascular risk factors, stratified by CHA2DS2-VASc score (> 2 vs < 2) and presence/absence of COPD. To detect AF appearance, patients underwent, every 6 months, physical examination, standard 12‑lead electrocardiog…

AdultMalemedicine.medical_specialtyCHA2DS2-VASc scorePulmonary diseasePredictive Value of Test030204 cardiovascular system & hematologySeverity of Illness IndexFollow-Up Studie03 medical and health sciencesPulmonary Disease Chronic Obstructive0302 clinical medicineInternal medicinemedicineCompetitive interaction030212 general & internal medicineProspective cohort studyAgedCOPDbusiness.industryProportional hazards modelIncidence (epidemiology)Chronic obstructive pulmonary diseaseIncidenceAtrial fibrillationMiddle Agedmedicine.diseaseCardiovascular riskAtrial fibrillationProspective Studieatrial fibrillation; cha(2)ds(2)-vasc score; cardiovascular risk; chronic obstructive pulmonary diseaseCHA2DS2–VASc scoreCardiologyFemaleCohort StudiebusinessCardiology and Cardiovascular MedicineHuman
researchProduct

Sympathovagal balance and 1-h postload plasma glucose in normoglucose tolerant hypertensive patients.

2015

AIMS: Normoglucose tolerant (NGT) subjects with a 1-h postload plasma glucose (PLPG) value ≥155 mg/dL have an increased risk of type-2 diabetes and subclinical organ damage. Heart rate variability (HRV) reflects cardiac autonomic balance, frequently impaired in course of diabetes. At this time, no data support the association between 1-h PLPG and HRV; thus, we investigated the possible association between 1-h PLPG and HRV. METHODS: We enrolled 92 never-treated hypertensive subjects (56 women, 36 men), aged 55 ± 9.8 years. During OGTT, the patients underwent electrocardiographic recordings to evaluate HRV in the time domain (SDNN). Insulin sensitivity was assessed by Matsuda index. RESULTS: …

AdultBlood GlucoseMalemedicine.medical_specialtySettore MED/09 - Medicina Internaendocrine system diseasesglucose toleranceInsulin resistance Heart rate variability Glucose tolerance Essential hypertensionEndocrinology Diabetes and Metabolismmedicine.medical_treatment030209 endocrinology & metabolism030204 cardiovascular system & hematologyEssential hypertensionAutonomic Nervous Systeminsulin resistance heart rate variability glucose tolerance essential hypertensionImpaired glucose tolerance03 medical and health sciences0302 clinical medicineEndocrinologyInsulin resistanceHeart RateInternal medicineDiabetes mellitusinsulin resistanceGlucose IntoleranceInternal MedicineMedicineHeart rate variabilityHomeostasisHumansSubclinical infectionBalance (ability)Agedbusiness.industryInsulinheart rate variabilityessential hypertensionnutritional and metabolic diseasesGeneral MedicineGlucose Tolerance TestMiddle Agedmedicine.diseaseEndocrinologyDiabetes Mellitus Type 2HypertensionCardiologyFemalebusinesshormones hormone substitutes and hormone antagonists
researchProduct

Prevalence of use and appropriateness of antidepressants prescription in acutely hospitalized elderly patients.

2019

Depression is often under-recognized in older patients, even if antidepressants (AD) are commonly prescribed, with a prevalence of use that increase with ageing [ 1 ]. Nevertheless, even if a diagnosis of depression is established, inappropriate treatment can occur [ 2 ]. Beers criteria are the most widely screening tools used to detect inappropriate prescription of drugs in people aged 65 years or more [ 3 ]. Since 2010, attempts to adapt the Beers' criteria have been made in Europe [ 4 , 5 ]. Tricyclic drugs are the ADs to be always avoided in the elderly, owing to their anticholinergic side effects, such as cognitive impairment, delirium, urinary retention and falls [ 3 ]. Selective sero…

Malemedicine.medical_specialtySocio-culturaleInappropriate Prescribing-Potentially inappropriate medication olderPractice Patternsdepression hospitalized patients drugselderlydrugsantidepressivi anzianoPolypharmacy | Inappropriate Prescribing | Medications PIMsantidepressant agent escitalopram paroxetineInternal MedicinemedicineHospital dischargeolderEscitalopramHumansLS4_4Medical prescriptionPractice Patterns Physicians'Depression (differential diagnoses)AgedPolypharmacySertralinePhysicians'antidepressantbusiness.industryTrazodonehospitalized patientsAntidepressive AgentsHospitalizationAcute Disease; Aged; Antidepressive Agents; Female; Humans; Inappropriate Prescribing; Italy; Male; Practice Patterns Physicians'; Hospitalizationantidepressants; elderlyItalyantidepressantsEmergency medicinedepressionAcute DiseasePolypharmacy Inappropriate Prescribing Medications PIMDeliriumFemalePotentially inappropriate medicationmedicine.symptombusinessmedicine.drugEuropean journal of internal medicine
researchProduct

Immunity, Inflammation and Heart Failure. Their Role on Cardiac Function and Iron Status

2019

Aims: Heart failure is a clinical syndrome characterized by subclinical systemic inflammation and immune system activation associated with iron deficiency. No data exist on the various activations of immune-mediated mechanisms of inflammation in heart failure patients with reduced/preserved ejection fraction. We aimed to (1) investigate possible differences in inflammatory parameters and oxidative stress, and (2) detect a different iron status between groups. Materials and Methods: We enrolled 50 consecutive Caucasian outpatients with heart failure. All patients underwent echocardiographic measurements, laboratory determinations, evaluation of iron status and Toll-like receptors, and NF-κB …

Male0301 basic medicineheart failureSystemic inflammationGastroenterologyVentricular Function LeftElectrocardiographychemistry.chemical_compound0302 clinical medicineiron deficiencyImmunology and Allergyejection fraction; heart failure; inflammation; iron deficiency; toll-like receptorejection fractionOriginal ResearchAged 80 and overEjection fractionbiologymedicine.diagnostic_testToll-Like ReceptorsIron deficiencyMiddle AgedHeart Function TestsSerum ironCytokinesFemaleDisease SusceptibilityInflammation Mediatorsmedicine.symptomlcsh:Immunologic diseases. AllergyCardiac function curvemedicine.medical_specialtyIronImmunology03 medical and health sciencesHepcidinsInternal medicinemedicineHumansAgedCreatininebusiness.industryImmunitymedicine.diseaseFerritinOxidative Stress030104 developmental biologychemistryinflammationHeart failurebiology.proteintoll-like receptorlcsh:RC581-607businessBiomarkers030215 immunology
researchProduct

Heart failure and chronic kidney disease in a registry of internal medicine wards

2014

Background: The aim of the present study was to evaluate the association between heart failure (HF) and chronic kidney disease (CKD) in tertiary care centers using the clinical records of patients enrolled in internal medicine departments.Patients and methods: We used the clinical records of 1380 elderly patients to identify patients with a history of HF and CKD using admission ICD codes and glomerular filtration rate (GFR) formulas. Magnitude and strength of such associations were investigated by univariable and multivariable analysis.Results: Of the 1380 patients enrolled, 27.9% had HF (age 80 ± 7, BMI 27 ± 6 kg/m2) and 17.4% CKD (age 81 ± 7, BMI 26.8 ± 6 kg/m2). Both groups were signific…

medicine.medical_specialtyChronic kidney disease; Elderly; Heart failure; REPOSI; Gerontology; Geriatrics and GerontologyHeart failure; Elderly; Chronic kidney disease; REPOSIChronic kidney disease; Elderly; Heart failure; REPOSI; Humans; Sleep Apnea Syndromes; Noninvasive Ventilation; Gerontology; Geriatrics and GerontologyChronic kidney disease; Elderly; Heart failure; REPOSIRenal functionHeart failure; chronic kidney disease; elderly; registry; REPOSIHeart failureregistryTertiary careSleep Apnea SyndromeElderlySleep Apnea SyndromesInternal medicineChronic kidney diseaseEpidemiologymedicineHumansNoninvasive Ventilationbusiness.industryREPOSIChronic kidney disease; Elderly; Heart failure; REPOSI; Humans; Sleep Apnea Syndromes; Noninvasive Ventilation; Geriatrics and Gerontology; Gerontologymedicine.diseaseHeart failureHeart failure Elderly Chronic kidney disease REPOSIIcd codesGeriatrics and GerontologybusinessClinical recordBody mass indexGerontologyKidney diseaseHuman
researchProduct

The UCP2 -866 G>A promoter region polymorphism is associated with nonalcoholic steatohepatitis

2015

Background & Aims Uncoupling protein 2 - UCP2 - regulates mitochondrial lipid fluxes and reactive oxygen species production by the respiratory chain. The −866 G>A UCP2 promoter region polymorphism has been linked to insulin resistance and lipid metabolism. The aim of this study was to assess whether the −866 G>A UCP2 polymorphism predisposes to nonalcoholic steatohepatitis in patients at risk, and the relationship with lipid metabolism and hepatic UCP2 expression. Methods We considered 688 Italian patients who underwent liver biopsy for suspected NASH, and 232 healthy controls. The UCP2 −866 G>A polymorphism was determined by allele specific oligonucleotide probes, hepatic UCP2 mRNA levels …

AdultMalemedicine.medical_specialtyGenotypeRespiratory chainGene ExpressionBiologyIon ChannelsMitochondrial Proteinsgenetic polymorphism; lipid metabolism;liver; mitochondria; nonalcoholic steatohepatitis; uncoupling protein-2Insulin resistanceNon-alcoholic Fatty Liver DiseaseRisk FactorsDiabetes mellitusInternal medicineGenotypemedicineHumansUncoupling Protein 2Promoter Regions GeneticUncoupling protein-2AllelesAgedPolymorphism GeneticGenetic polymorphismmedicine.diagnostic_testHepatologyLipid metabolismMiddle Agedmedicine.diseaseImpaired fasting glucoseMitochondriaEndocrinologyLogistic ModelsLipid metabolismLiverLiver biopsyCase-Control StudiesFemaleSteatosisInsulin ResistanceNonalcoholic steatohepatiti
researchProduct

Bempedoic Acid: A New Tool for LDL-Cholesterol Control in Patients with Coronary Artery Disease

2022

General MedicineCardiology and Cardiovascular MedicineReviews in Cardiovascular Medicine
researchProduct

Cardiovascular effects of glucagon-like peptide-1 receptor agonist therapies in patients with type 1 diabetes

2017

Type 1 diabetesbusiness.industryEndocrinology Diabetes and Metabolism030209 endocrinology & metabolism030204 cardiovascular system & hematologyPharmacologymedicine.disease03 medical and health sciences0302 clinical medicineEndocrinologyText miningInternal MedicinemedicineIn patientbusinessGlucagon-like peptide 1 receptorDiabetes, Obesity and Metabolism
researchProduct

Choice and Outcomes of Rate Control versus Rhythm Control in Elderly Patients with Atrial Fibrillation: A Report from the REPOSI Study

2018

Background: Among rate-control or rhythm-control strategies, there is conflicting evidence as to which is the best management approach for non-valvular atrial fibrillation (AF) in elderly patients. Design: We performed an ancillary analysis from the ‘Registro Politerapie SIMI’ study, enrolling elderly inpatients from internal medicine and geriatric wards. Methods: We considered patients enrolled from 2008 to 2014 with an AF diagnosis at admission, treated with a rate-control-only or rhythm-control-only strategy. Results: Among 1114 patients, 241 (21.6%) were managed with observation only and 122 (11%) were managed with both the rate- and rhythm-control approaches. Of the remaining 751 patie…

MaleAnti-Arrhythmia Agents/therapeutic useantiarrhythmic agentComorbidityAged; Aged 80 and over; Anti-Arrhythmia Agents; Atrial Fibrillation; Comorbidity; Diabetes Mellitus; Female; Heart Failure; Heart Rate; Hospitalization; Humans; Male; Odds Ratio; Polypharmacy; Prevalence; Geriatrics and Gerontology; Pharmacology (medical)030204 cardiovascular system & hematologyanticoagulant agentDiabetes Mellitus/drug therapy0302 clinical medicineHeart RateAtrial Fibrillation80 and overOdds RatioPrevalencePharmacology (medical)030212 general & internal medicineLS4_4Aged 80 and overantiarrhythmic agent anticoagulant agent antithrombocytic agent calcium channel blocking agent digoxinHeart Rate/drug effectsDiabetes MellituAtrial fibrillationantithrombocytic agentdigoxinHospitalizationAnti-Arrhythmia AgentFemaleAnti-Arrhythmia AgentsHumanmedicine.medical_specialtySocio-culturale-Geriatrics and Gerontology; Pharmacology (medical)03 medical and health sciencesInternal medicineDiabetes mellitusHeart rateantiarrhythmic agent; anticoagulant agent; antithrombocytic agent; calcium channel blocking agent; digoxinmedicineDiabetes MellitusHumansAgedPolypharmacyHeart Failurebusiness.industryAtrial Fibrillation/drug therapyOdds ratiomedicine.diseaseHeart Failure/drug therapyComorbidityConfidence intervalcalcium channel blocking agentHeart failurePolypharmacyAged; Aged 80 and over; Anti-Arrhythmia Agents; Atrial Fibrillation; Comorbidity; Diabetes Mellitus; Female; Heart Failure; Heart Rate; Hospitalization; Humans; Male; Odds Ratio; Polypharmacy; PrevalenceGeriatrics and Gerontologybusiness
researchProduct

Phenotyping normal kidney function in elderly patients with type 2 diabetes: a cross-sectional multicentre study

2018

AimsType 2 diabetes (T2D) accelerates the decline in glomerular function; however, some individuals do not develop chronic kidney disease despite advanced age and long-lasting T2D. We aimed to phenotype patients with T2D aged 80years or older who presented with a fully preserved kidney function.MethodsFrom an Italian population of 281,217 T2D outpatients, we collected data on demographics, anthropometrics, diabetes duration, HbA1c, fasting plasma glucose, lipids, liver enzymes, estimated glomerular filtration rate (eGFR), albumin excretion rate (AER), chronic complications, and medication use. We primarily compared patients with a fully preserved kidney function (eGFR>90ml/min/1.73m(2) and …

MaleEpidemiologyEndocrinology Diabetes and MetabolismType 2 diabetes030204 cardiovascular system & hematologyKidneyType 2 diabeteSettore MED/13 - Endocrinologia0302 clinical medicineEndocrinology80 and overMedicineDiabetic Nephropathies030212 general & internal medicineAged 80 and overeducation.field_of_studyType 2 diabetesGeneral MedicineEpidemiology; Insulin resistance; Nephropathy; Protective; Type 2 diabetesDiabetes and MetabolismPhenotypeLipotoxicityFemaleType 2HumanGlomerular Filtration Ratemedicine.medical_specialtyPopulationRenal functionEpidemiology; Insulin resistance; Nephropathy; Protective; Type 2 diabetes; Internal Medicine; Endocrinology Diabetes and Metabolism; EndocrinologyNephropathyEpidemiology; Insulin resistance; Nephropathy; Protective; Type 2 diabetes; Aged 80 and over; Diabetes Mellitus Type 2; Diabetic Nephropathies; Female; Glomerular Filtration Rate; Humans; Kidney; Male; Phenotype; Internal Medicine; Endocrinology Diabetes and Metabolism; Endocrinology03 medical and health sciencesInsulin resistanceInternal medicineDiabetes mellitusDiabetes MellitusInternal MedicineHumanseducationAgedbusiness.industryInsulin resistancemedicine.diseaseNephropathyProtectiveDiabetes Mellitus Type 2Diabetic NephropathiebusinessKidney disease
researchProduct

Efficacy and Safety of Degludec versus Glargine in Type 2 Diabetes.

2017

BACKGROUND Degludec is an ultralong-Acting, once-daily basal insulin that is approved for use in adults, adolescents, and children with diabetes. Previous open-label studies have shown lower day-To-day variability in the glucose-lowering effect and lower rates of hypoglycemia among patients who received degludec than among those who received basal insulin glargine. However, data are lacking on the cardiovascular safety of degludec. METHODS We randomly assigned 7637 patients with type 2 diabetes to receive either insulin degludec (3818 patients) or insulin glargine U100 (3819 patients) once daily between dinner and bedtime in a double-blind, treat-To-Target, event-driven cardiovascular outco…

Insulin degludecBlood GlucoseMalemedicine.medical_treatmentDEVOTE Study GroupInsulin GlargineType 2 diabetesKaplan-Meier Estimate030204 cardiovascular system & hematologylaw.inventiondiabetes ; insulin0302 clinical medicineRandomized controlled triallawCardiovascular DiseaseGLUCOSE CONTROL11 Medical and Health SciencesRISKCOMPLICATIONSOUTCOMESIncidenceGeneral MedicineMiddle AgedInsulin Long-ActingVARIABILITYCardiovascular Diseasesdiabetes mellitusFemaleLife Sciences & BiomedicineHumanmedicine.drugmedicine.medical_specialty030209 endocrinology & metabolismAged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus Type 2; Double-Blind Method; Female; Humans; Hypoglycemia; Hypoglycemic Agents; Incidence; Insulin Glargine; Insulin Long-Acting; Kaplan-Meier Estimate; Male; Middle Aged; Medicine (all)HypoglycemiaBedtimeArticleEVENTS03 medical and health sciencesHYPOGLYCEMIAMedicine General & InternalDouble-Blind MethodInternal medicineDiabetes mellitusGeneral & Internal MedicinemedicineHumansHypoglycemic AgentsIntensive care medicineMETAANALYSISAgedScience & TechnologyHypoglycemic AgentInsulin glarginebusiness.industryInsulinmedicine.diseaseDiabetes Mellitus Type 2businessBASAL INSULIN
researchProduct

Sex-Differences in the Pattern of Comorbidities, Functional Independence, and Mortality in Elderly Inpatients: Evidence from the RePoSI Register

2019

Background: The RePoSi study has provided data on comorbidities, polypharmacy, and sex dimorphism in hospitalised elderly patients. Methods: We retrospectively analysed data collected from the 2010, 2012, 2014, and 2016 data sets of the RePoSi register. The aim of this study was to explore the sex-differences and to validate the multivariate model in the entire dataset with an expanded follow-up at 1 year. Results: Among 4714 patients, 51% were women and 49% were men. The disease distribution showed that diabetes, coronary artery disease, chronic obstructive pulmonary disease, chronic kidney disease, and malignancy were more frequent in men but that hypertension, anaemia, osteoarthritis, de…

medicine.medical_specialtyMultivariate analysislcsh:MedicineSocio-culturaleDisease030204 cardiovascular system & hematologyelderlyArticleCoronary artery disease03 medical and health sciences0302 clinical medicineInternal medicineMedicine030212 general & internal medicineDepression (differential diagnoses)Polypharmacybusiness.industrylcsh:RGeneral Medicinemedicine.diseaseComorbidityelderly sex profiles disease distribution in-hospital mortality 3-month mortality 1-year mortalityMood disordersdisease distribution1-year mortality3-month mortalitysex profilesbusiness1-year mortality; 3-month mortality; disease distribution; elderly; in-hospital mortality; sex profilesKidney diseasein-hospital mortality
researchProduct

Pattern of comorbidities and 1-year mortality in elderly patients with COPD hospitalized in internal medicine wards: data from the RePoSI Registry

2020

Currently, chronic obstructive pulmonary disease (COPD) represents the fourth cause of death worldwide with significant economic burden. Comorbidities increase in number and severity with age and are identified as important determinants that influence the prognosis. In this observational study, we retrospectively analyzed data collected from the RePoSI register. We aimed to investigate comorbidities and outcomes in a cohort of hospitalized elderly patients with the clinical diagnosis of COPD. Socio-demographic, clinical characteristics and laboratory findings were considered. The association between variables and in-hospital, 3-month and 1-year follow-up were analyzed. Among 4696 in-patient…

Malemedicine.medical_specialtyChronic ObstructiveCirrhosisSocio-culturaleComorbidity030204 cardiovascular system & hematologycomorbiditieselderlyPulmonary Disease03 medical and health sciencesPulmonary Disease Chronic Obstructive0302 clinical medicineInternal medicinemedicine80 and overCOPDHumans030212 general & internal medicineLS4_4RegistriesHospital MortalityCOPD comorbidities elderly internal medicine in-hospital mortality.Depression (differential diagnoses)Cause of deathAgedRetrospective Studies1-year mortality; 3-month mortality; COPD; comorbidities; elderly; internal medicine; in-hospital mortalityAged 80 and overCOPDbusiness.industry1-year mortality; 3-month mortality; COPD comorbidities elderly internal medicine in-hospital mortalitymedicine.diseaseIm - Original1-year mortality; 3-month mortality; COPD comorbidities elderly internal medicine in-hospital mortality; Aged; Aged 80 and over; Comorbidity; Female; Humans; Internal Medicine; Male; Pulmonary Disease Chronic Obstructive; Registries; Retrospective Studies; Hospital Mortalityinternal medicineClinical diagnosisCohortEmergency Medicine1-year mortality3-month mortalityCOPD comorbidities elderly internal medicine in-hospital mortality1-year mortality 3-month mortality COPD comorbidities elderly internal medicine in-hospital mortality.Observational studyFemalebusiness1 year mortalityin-hospital mortality
researchProduct

Adherence to antithrombotic therapy guidelines improves mortality among elderly patients with atrial fibrillation: insights from the REPOSI study

2016

Background: Atrial fibrillation (AF) is associated with a substantial risk of thromboembolism and mortality, significantly reduced by oral anticoagulation. Adherence to guidelines may lower the risks for both all cause and cardiovascular (CV) deaths. Methods: Our objective was to evaluate if antithrombotic prophylaxis according to the 2012 European Society of Cardiology (ESC) guidelines is associated to a lower rate of adverse outcomes. Data were obtained from REPOSI; a prospective observational study enrolling inpatients aged ≥65 years. Patients enrolled in 2012 and 2014 discharged with an AF diagnosis were analysed. Results: Among 2535 patients, 558 (22.0 %) were discharged with a diagnos…

Antithrombotic therapy; Atrial fibrillation; Elderly; Guidelines; Outcomes; Cardiology and Cardiovascular MedicineMaleRegistrieTime Factorsantithrombotic therapy; atrial fibrillation; elderly; guidelines; outcomesAtrial fibrillation (AF)Practice PatternsKaplan-Meier Estimate030204 cardiovascular system & hematologyGuidelineoutcomesCoronary artery disease0302 clinical medicineElderlyRisk FactorsAtrial FibrillationAntithrombotic80 and overAge Factor030212 general & internal medicineRegistriesguidelinesAntithrombotic therapy Atrial fibrillation Elderly Guidelines OutcomesPractice Patterns Physicians'OutcomeAged 80 and overFibrinolytic AgentAge FactorsAtrial fibrillationGeneral MedicineTreatment OutcomeItalyAtrial fibrillation (AF) thromboembolism antithrombotic prophylaxisPractice Guidelines as TopicCardiologyFemaleGuideline AdherenceCardiology and Cardiovascular MedicineHumanAntithrombotic therapy; Atrial fibrillation; Elderly; Guidelines; Outcomes; Age Factors; Aged; Aged 80 and over; Atrial Fibrillation; Chi-Square Distribution; Female; Fibrinolytic Agents; Guideline Adherence; Humans; Italy; Kaplan-Meier Estimate; Logistic Models; Male; Practice Patterns Physicians'; Proportional Hazards Models; Registries; Risk Assessment; Risk Factors; Thromboembolism; Time Factors; Treatment Outcome; Practice Guidelines as Topic; Cardiology and Cardiovascular Medicinemedicine.medical_specialtyLogistic ModelTime FactorSocio-culturaleLower riskRisk Assessment03 medical and health sciencesFibrinolytic AgentsInternal medicineThromboembolismmedicineHumansProportional Hazards ModelsAgedAntithrombotic therapyPhysicians'Chi-Square Distributionbusiness.industryProportional hazards modelRisk FactorSettore MED/09 - MEDICINA INTERNAGuidelinethromboembolismmedicine.diseaseAtrial fibrillationLogistic ModelsProportional Hazards Modelantithrombotic prophylaxisbusinessChi-squared distributionFibrinolytic agent
researchProduct

Clinical evaluation of bempedoic acid for the treatment of hyperlipidaemia.

2021

Bempedoic acid (BA) is a novel first-in-class oral lipid-lowering therapy. BA has been approved by the European Medicinal Agency and Food and Drug Administration and has been commercialised throughout Europe since the end of 2020 as an add-on therapy in patients at high/very-high cardiovascular risk that are not at LDL-C goals with current lipid-lowering treatments. Recently, Italian lipid management experts gathered to discuss several open questions on BA characteristics and BArelated practical clinical issues. The panel permitted collection of its opinions in a ten Q&amp;A format. Aim: The aim of this viewpoint is to discuss and answer several open questions on BA characteristics and BA-r…

ATP citrate lyaseEndocrinology Diabetes and MetabolismMedicine (miscellaneous)HyperlipidemiasPharmacologyLipid-lowering therapyLipid-lowering treatmentMedicineLDL-cholesterolHumansDicarboxylic AcidsHypolipidemic AgentsLdl cholesterolNutrition and DieteticsLipid managementbusiness.industryNovel LDL-C treatment.Fatty AcidsCholesterol LDLBempedoic acidNovel LDL-C treatmentATP citrate lyaseATP citrate lyase; bempedoic acid; LDL-cholesterol; lipid-lowering treatment; novel LDL-C treatmentLipid loweringCardiology and Cardiovascular MedicinebusinessClinical evaluationBempedoic acidNutrition, metabolism, and cardiovascular diseases : NMCD
researchProduct